Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

BERLIN – November 27, 2020. Morrison & Foerster LLP (MoFo) advised Medios AG (Medios), a specialty pharmaceutical company listed on the SDAX, on taking over the Hamburg specialty pharmaceutical wholesaler Cranach from the holding

Morrison & Foerster Advises Medios AG on the Takeover of Pharmaceutical Wholesaler Cranach

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

BERLIN – November 27, 2020. Morrison & Foerster LLP (MoFo) advised Medios AG (Medios), a specialty pharmaceutical company listed on the SDAX, on taking over the Hamburg specialty pharmaceutical wholesaler Cranach from the holding company BMSH GmbH. The transaction value amounts to over 120 million euro. Approval from the Federal Cartel Office is still pending. Cranach focuses on pharmaceuticals in the fields of neurology, hematology, and endocrinology, as well as ophthalmology, rheumatology, and oncology. The acquisition of Cranach is intended to enable Medios to better position itself as a full-service provider in the specialty pharmaceutical sector.The MoFo team worked with managing partner Dr. Dirk Besse on the transaction, which was structured as a contribution in kind against the issue of over four million new Medios shares. MoFo has been advising Medios AG on an ongoing basis on capital market and corporate law matters ever since supporting its successful reverse IPO in 2017.Morrison & Foerster’s team: Dr. Dirk Besse, managing partner (Corporate/M&A); Dr. Sebastian Schwalme, counsel (Corporate/M&A); Paula Paprocki, associate (Corporate/M&A); Julian Gebauer, associate (Corporate/M&A); Dr. Andreas Grünwald, partner (Antitrust); Dr. Wolfgang Schönig, partner (IP/Pharma); Robert Grohmann, Associate (IP/Pharma); (Dr. Jens-Uwe Hinder, partner (Tax); Dr. Angela Kerek, partner (Finance)Seller’s legal advisor: FGvW Friedrich Graf von Westfalen & Partner Rechtsanwälte mbB: Dr. Stefan Lammel, Dr. Morton Douglas, Dr. Stephanie von Riegen, and Constantin CadmusNotary: Ralph Negelein (Heuking Kühn)More information on the transaction can be found at the following links:<a href="https://medios.ag/newsdetailview/umsatzanstieg-auf-mehr-als-1-mrd/64?cHash=c659e5e08276107feb799b69126e2ee7" target="_blank">News: Medios AG: Increase in sales to more than 1 billion euro</a><a href="https://www.investegate.co.uk/article.aspx?id=20201126173049EBEHY" target="_blank">Medios AG: Medios AG acquires Cranach Pharma GmbH; issue of 4,180,000 new Medios shares; significant increase in sales expected in 2021 to over €1 billion</a>

Morrison & Foerster Advises Medios AG on the Takeover of Pharmaceutical Wholesaler Cranach